ELP1 and Fabry disease: Additionally, these two FD stem cell models were used for validating the potency of therapeutic agents such as kinetin, a cytokinin that has been shown to increase IKBKAP mRNA and protein expression in FD cell lines and in vivo models [25–27] as well as in leukocytes of healthy carriers of the FD mutation [28].